

North Central Cancer Treatment Group

N064B, Randomized Phase II Trial of Panitumumab, Erlotinib, and Gemcitabine vs. Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma

Addendum 8 – October 15, 2010

Summary

- In compliance with the NCI/CTEP mandate (dated May 28, 2010), expedited adverse event reporting requirements were converted from CTCAE v3.0 to CTCAE v4.0 (affected sections 10.1 and 10.11) while routine data collection via Case Report Forms (which includes the Notification Form: Grade 4 or 5 Non-AER Reportable Events/Hospitalization Form) will remain using CTCAE v3.0 (clarifications added to sections 8.11, 8.12, 10.21, 10.22, 10.3, 10.31, 16.11, and 16.52). Effective January 1, 2011, expedited reporting via ADEERS must use CTCAE v4.0 while the remainder of the data collection for legacy trials will continue to use CTCAE v3.0.
- Per NCI, the Secondary AML/MDS Report Form will no longer be used. Therefore, Sections 10 and 18 have been revised accordingly

Replacement pages are included. Please incorporate into the protocol and keep this addendum.

Title page Revised NCI version date and Addendum 8 have been added.

Section 8.0 **Dosage Modification Based on Adverse Events**
Pages 32-36: The first column headers in the Sections 8.11 and 8.12 tables have been revised for clarification as follows:

CTCAE v3.0 CATEGORY

Section 10.0 Adverse Event (AE) Reporting and Monitoring

Page 40:

Section 10.1 and Section 10.11 have been revised as follows to update the required AE reporting from CTCAE v3.0 to CTCAE v4.0.

- 10.1 ~~This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 for adverse event monitoring and reporting. The CTCAE v3.0 can be accessed from the CTEP home page <http://ctep.cancer.gov>.~~ **CTCAE term (AE description) and grade: The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized until December 31, 2010 for AE reporting. CTCAE v4.0 will be utilized for expedited adverse event reporting only, beginning January 1, 2011. All appropriate treatment areas should have access to a copy of the CTCAE v3.0. A copy of the CTCAE version 4.0 can be downloaded from the CTEP web site (<http://ctep.cancer.gov>).**

10.11 Adverse event monitoring and reporting is a routine part of every ...

Expedited adverse event reporting requires submission of an electronic Adverse Event Expedited Reporting System (AdEERS)...

Effective with Addendum 8, and beginning January 1, 2011, expedited AdEERS reporting for this protocol has been updated by the NCI/CTEP to use CTCAE v4.0. Therefore;

- 1) Events requiring expedited reporting through AdEERS must be reported through the AdEERS system in CTCAE v4.0.**
- 2) The events reported via AdEERS must ALSO be reported through routine reporting (i.e., Case Report Forms) using CTCAE v3.0.**
- 3) Routine data collection via Case Report Forms, including the "Notification Form: Grade 4 or 5 Non-AER Reportable Events/Hospitalization Form", will remain using CTCAE v3.0 for this study.**

Page 41:

The second bullet under Section 10.21 table has been revised for clarification as follows:
Any medical event equivalent to CTCAE v4.0 grade 3, 4, or 5...

A new fourth bullet has been added under Section 10.21 due to the removal of the Secondary AML/MDS Report form. The following text has been added:

- **SECONDARY MALIGNANCIES (defined as “cancer caused by treatment for a previous malignancy”, e.g., treatment with radiation or chemotherapy) are to be reported through AdEERS, as noted in Section 10.22. Secondary malignancies are not considered metastasis of the initial neoplasm. Secondary malignancy is unrelated to the first cancer that was treated, and may occur months or even years after initial treatment.**

Note: Second Primary malignancy (malignancy not due to prior treatment) should not be reported through AdEERS.

Page 42: Text has been revised in the second column of the “Secondary AML/MDS” row of Section 10.22 due to the removal of the Secondary AML/MDS Report Form. Changes are as follows:

Reporting for this event required during and after completion of study treatment, **via AdEERS.**

Through December 31, 2010, continue using CTCAE v3.0: Report Myelodysplasia as “Blood/Bone Marrow - Myelodysplasia” and Leukemias as “Blood/Bone Marrow - Other (Specify, ___)”.

Beginning January 1, 2011, AdEERS will only accept CTCAE v4.0 for this study: Report these events using “Neoplasms benign, malignant and unspecified (including cysts and polyps) - Other, specify”..

~~Submit the NCI/CTEP Secondary AML/MDS Report form within 15 days via fax or mail to the NCCTG SAE Coordinator, NCCTG Operations Office, 200 First Street SW, Rochester, MN 55905, Fax (507)284 9628. The Operations Office will submit to NCI.~~

Text has been added to the “Other Grade 4 or 5 Events...” row, second paragraph in the right hand column of Section 10.22 for clarification as follows:

Submit the NCCTG Notification Form Grade 4 or 5 Non-AER Reportable Events/Hospitalization electronically via the NCCTG Remote Data Entry System within 5 working days of the date the CRA is aware of the event(s) necessitating the form, **using CTCAE v3.0.**

Text has been added at the bottom of the table (right hand column) in Section 10.22 for clarification, as follows:

You must use CTCAE v3.0 for data submission with this form. The events reported on this form must also appear on the Case Report Forms (i.e., routine data) for this study.

Page 43: Section 10.3 and Section 10.31 have been revised for clarification. In Section 10.3 the first column header in the chart has added **CTCAE v3.0** and Section 10.31 has been revised as follows:

10.31 Submit to the NCCTG Research Base via the Nadir/AE Log the following AEs **using CTCAE v3.0** experienced by a patient and not...

Section 16.0 Statistical Considerations and Methodology

Page 74: The first column header in the toxicity table in Section 16.11 has been revised for clarification as follows:

Toxicity (**CTCAE v3.0**)

Page 76: The last sentence in the first paragraph of Section 16.52 has been added for clarification as follows:

CTCAE v3.0 will be used to determine grading for these stopping rules.

Section 18.0 Records and Data Collection Procedures

Page 87: With the removal of the Secondary AML/MDS Report Form, the row for the “Secondary AML/MDS Report Form” has been deleted. Secondary AML/MDS is now reported through AdEERS, see Section 10.22.